Albany, NY -- (SBWIRE) -- 07/30/2019 -- Waldenstrom Macroglobulinemia Market Insights, Epidemiology and Market Forecast-2028
1. There were a total of 32,852 Waldenstrom Macroglobulinemia total 7MM prevalent cases in 2017.
2. The 7MM Waldenstrom Macroglobulinemia Incident population was estimated to be 3817 cases in 2017.
3. There are 8247 males and 4123 females suffering from Waldenstrom Macroglobulinemia in 2017 in the US.
DelveInsight launched a new report on Waldenstrom Macroglobulinemia Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Waldenstrom Macroglobulinemia market report covers a descriptive overview and comprehensive insight of the Waldenstrom Macroglobulinemia epidemiology and Waldenstrom Macroglobulinemia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Waldenstrom Macroglobulinemia market report provides insights on the current and emerging therapies.
3. Waldenstrom Macroglobulinemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Waldenstrom Macroglobulinemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Waldenstrom Macroglobulinemia market.
Request for sample pages
"Waldenstrom Macroglobulinemia overall incidence was higher in males than females."
Waldenstrom Macroglobulinemia is the lymphoplasmacytic lymphoma characterized by the presence of an immunoglobulin M (IgM) monoclonal gammopathy in the blood and monoclonal small lymphocytes and lymphoplasmacytic cells in the bone marrow. It is a rare type of non-Hodgkin lymphoma (NHL) accounts for only 5% of indolent cases of NHL. The current Waldenstrom Macroglobulinemia treatment regimen is based completely to improve symptoms, to cease the growth of the tumour and prevent further progression. The low-grade cases of the disease are manageable with appropriate Waldenstrom Macroglobulinemia therapies but the advanced stage cases may create the threat of high morbidity and mortality.
Waldenstrom Macroglobulinemia could be symptomatic and asymptomatic. Asymptomatic Waldenstrom Macroglobulinemia patients may not need immediate treatment if they are otherwise healthy and the disease is not causing any problems. In these situations, patients are closely monitored, and active Waldenstrom Macroglobulinemia treatment begins if symptoms develop or the IgM level increases.
The dynamics of Waldenstrom Macroglobulinemia market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2017–2028. The current Waldenstrom Macroglobulinemia market is dependent on the only approved drug Imbruvica (Ibrutinib), chemotherapy, and off-label use of other targeted therapies. The robust pipeline, emerging therapies, increasing awareness, and education and improvement in treatment are stimulating the growth Waldenstrom Macroglobulinemia market. With the advent of orally available nonmyelotoxic and non-neurotoxic agents, long-term oral maintenance therapy will be possible with the potential decrease in Incident of second malignancies and transformation.
The launch of the emerging therapies is expected to significantly impact Waldenstrom Macroglobulinemia treatment scenario in the upcoming years:-
Drugs covered
1. BGB-3111
2. Everolimus (RAD-001)
3. Zydelig (Idelalisib)
And many others
The key players in Waldenstrom Macroglobulinemia market are:
1. BeiGene
2. Novartis
3. Gilead Sciences
And many others
Table of contents
1. Key Insights
2. Waldenstrom Macroglobulinemia Market Overview at a Glance
3. Waldenstrom Macroglobulinemia Disease Background and Overview
4. Waldenstrom Macroglobulinemia Epidemiology and Patient Population
5. Waldenstrom Macroglobulinemia Country Wise-Epidemiology
6. United States
7. EU-5
8. Germany
9. France
10. Italy
11. Spain
12. United Kingdom
13. Japan
14. Waldenstrom Macroglobulinemia Treatment Algorithm
15. Waldenstrom Macroglobulinemia Unmet Needs
16. Waldenstrom Macroglobulinemia Marketed Drug
16.1. Imbruvica (Ibrutinib): Janssen/AbbVie
17. Waldenstrom Macroglobulinemia Emerging Therapies
18. BGB-3111- BeiGene
18.2. Everolimus (RAD-001)- Novartis
19. Zydelig (Idelalisib)- Gilead Sciences
20. Waldenstrom Macroglobulinemia 7 Major Market Analysis
21. Market Outlook by Country
21.1. The United States: Market Outlook
21.2. United States Market Size
21.3. EU-5 Countries: Market Outlook
21.4. Germany Market Size
21.5. France Market Size
21.6. Italy Market Size
21.7. Spain Market Size
21.8. United Kingdom Market Size
21.9. Japan: Market Outlook
22. Market Drivers
23. Market Barriers
24. Appendix
25. Waldenstrom Macroglobulinemia Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight